Spermicide used alone for contraception

Area of Science:

• Reproductive Health
• Contraception Research
• Clinical Trials

Background:

• Spermicides, used for millennia as contraceptives, are vaginal medications containing active ingredients like nonoxynol-9.
• Recent research has focused on comparing the efficacy and acceptability of various spermicide formulations.
• Understanding spermicide performance is crucial for reproductive health choices.

Purpose of the Study:

• To review all randomized controlled trials (RCTs) of spermicides used as standalone contraceptives.
• To assess the comparative efficacy and outcomes of different spermicide products and formulations.

Main Methods:

• Comprehensive search of multiple databases (e.g., CENTRAL, MEDLINE, EMBASE) up to July 2004 for relevant RCTs.
• Inclusion criteria focused on commercial products used alone for contraception with sufficient data on pregnancy rates.
• Data extraction by two independent reviewers; results presented descriptively due to high participant dropout rates.

Main Results:

• The largest trial indicated a lower contraceptive efficacy for a nonoxynol-9 52.5 mg gel compared to higher doses (100 mg, 150 mg).
• Pregnancy probabilities at six months varied significantly by nonoxynol-9 dose, but trial limitations due to participant loss were noted.
• Few significant efficacy differences were observed across other spermicide trials, and user characteristics appeared influential.

Conclusions:

• Pregnancy probability varied widely among spermicide trials, with a low-dose nonoxynol-9 gel showing inferior efficacy.
• User characteristics and behavior may play a more significant role in contraceptive outcomes than product specifics.
• High discontinuation rates and recruitment challenges complicate spermicide trial validity and interpretation.